T. Rowe Price Associates
RNA

T. Rowe Price Associates’s Atrium Therapeutics RNA Stock Holding History

T. Rowe Price Associates’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.8M Sell
1,472,984
-80,226
-5% -$1.05M ﹤0.01% 1151
2026
Q1 		$20.8M Buy
+1,553,210
New +$21.8M ﹤0.01% 1026

Other funds holding RNA

SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CL
CRCM LP San Francisco, California $152M AUM 26.3% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates's RNA Position: Q2 2026 in Review

T. Rowe Price Associates reduced its Atrium Therapeutics (RNA) stake by 5.2% in Q2 2026, selling an estimated $1.05M and leaving 1,472,984 shares worth $19.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1151.

T. Rowe Price Associates first reported a position in RNA in Q1 2026 and has held it in 2 quarters since. The position peaked at $20.8M in Q1 2026. 155 funds tracked by Wall St. Rank hold RNA as of Q2 2026.

  • T. Rowe Price Associates held 1,472,984 shares of Atrium Therapeutics worth $19.8M as of Q2 2026.
  • T. Rowe Price Associates sold 80,226 Atrium Therapeutics shares in Q2 2026, an estimated $1.05M.
  • Atrium Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1151 holding.
  • T. Rowe Price Associates first reported a position in Atrium Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • T. Rowe Price Associates's Atrium Therapeutics position peaked at $20.8M in Q1 2026.
  • 155 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.